Locally Advanced or Metastatic Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
Conditions
Interventions
Observation Group for ALK-positive non-small cell lung cancer treatment:None
Sponsors
Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital &Institute)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients voluntarily sign the informed consent form (ICF); 2.Age = 18 years old, regardless of gender; 3.Patients with pathologically confirmed locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC); 4.Planned to receive iruplinalkib treatment.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following conditions will be prohibited from enrolling in this study: 1. Mental abnormalities or inability to cooperate with examinations or follow-ups; 2. Known pregnant or lactating women; 3. Unable to sign the informed consent form; 4. The researcher determines other circumstances that are not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Real-World Progression-Free Survival (rwPFS);Overall Survival (OS);Time to Treatment Failure (TTF);Time to First Subsequent Therapy or Death (TFST); | — |
Countries
China
Contacts
Public ContactXudong Hu
Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital &Institute)
Outcome results
None listed